Loading
Diet, Metabolism, and Disease / Renal Diseases and Glomerulopathies · Journal article
Signal Transduction and Targeted Therapy · August 17, 2026
Raises a question worth testing. It does not answer one.
This preclinical work proposes a novel mechanism by which fructose directly binds to the TOM22 subunit of the mitochondrial outer membrane translocase complex, disrupting protein import and oxidative phosphorylation in podocytes and mouse models, independent of fructose metabolism. The finding is mechanistically interesting but remains at the level of hypothesis generation; it does not yet establish clinical relevance or provide evidence sufficient to change clinical practice.
Preclinical mechanistic study combining in vitro biochemistry, cell culture, and mouse models. Cultured podocytes and mice with fructose-induced injury models; no human subjects.. Intervention: Fructose exposure and disruption of fructose-TOM22 binding. Compared with: Control (untreated) or standard fructose exposure.
Fructose non-covalently binds to TOM22 and induces conformational changes in the TOM complex, blocking transmembrane translocation of mitochondrial ribosome subunits Disrupting the fructose-TOM22 binding recovers abnormal ribosome trafficking and restores oxidative phosphorylation in fructose-treated podocytes TOM structural remodeling ameliorates mitochondrial dysfunction and glomerular pathological lesions in mouse injury models
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work identifies a potential mechanistic pathway linking dietary fructose to mitochondrial and metabolic disease, but no quantitative efficacy data, sample sizes, or clinical outcomes are provided. Further translational and clinical studies would be needed before considering any therapeutic intervention based on disrupting fructose-TOM22 binding.
This is a mechanistic study using in vitro biochemistry and cell/animal models to propose a novel pathway; it raises a question about fructose's direct effects on mitochondria rather than providing clinical evidence ready to guide practice.
As stated by the source record.
This work identifies a potential mechanistic pathway linking dietary fructose to mitochondrial and metabolic disease, but no quantitative efficacy data, sample sizes, or clinical outcomes are provided. Further translational and clinical studies would be needed before considering any therapeutic intervention based on disrupting fructose-TOM22 binding.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Excessive dietary fructose consumption contributes to the rapidly increasing prevalence of obesity, metabolic syndrome, and chronic kidney disease worldwide, and accumulating preclinical evidence has confirmed that excess fructose exposure provokes severe mitochondrial dysfunction, which serves as a critical upstream driver of progressive metabolic disturbance and renal tissue injury. Conventionally, fructose-induced mitochondrial damage is thought to originate from harmful intermediate metabolites produced during intracellular fructose catabolism, while the potential direct pathogenic effect of intact unmetabolized fructose is largely overlooked. It remains unclear whether free fructose can directly target core mitochondrial complexes to initiate functional defects independent of its metabolic breakdown. Here, we report a fructose metabolism-independent mechanism in which fructose structurally remodels the translocase of the outer membrane (TOM) complex, obstructing the import of nuclear-encoded mitochondrial proteins and inhibiting mitochondrial ribosome biogenesis as well as oxidative phosphorylation. In vitro biochemical assays confirm that fructose non-covalently binds to TOM22 and induces subtle but functionally critical conformational changes in the TOM complex, thereby blocking the transmembrane translocation of mitochondrial ribosome subunits. Notably, disrupting the fructose-TOM22 binding efficiently recovers abnormal ribosome trafficking, restores compromised oxidative phosphorylation, and ameliorates mitochondrial dysfunction and glomerular pathological lesions in fructose-treated podocytes and mouse injury models. Our findings establish an innovative mechanistic paradigm that fructose acts as a direct allosteric modulator of mitochondrial membrane complexes, identifying TOM structural remodeling as a previously unrecognized molecular trigger of fructose-associated mitochondrial and metabolic disorders.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.